All In Biotech

Drug Trial Radar · NCT00277589

LISA-study : Levothyroxin in Nodular Goiter

TSH-adapted Therapy in a Large Randomized, Observer-blind, Placebo-controlled, Prospective Treatment Study of Patients With Nodular Goiter

Last checked: Nov 19, 2026Latest source record: Dec 4, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,024 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,024

Actual

Start

May 2004

Primary completion

Dec 2008

Study completion Dec 2008

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jan 16, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective: * To evaluate change in total volume of all nodules. Secondary objectives: * To evaluate change in goiter volume after a 12-months treatment, number of nodules and echogenicity of nodules.

Conditions

  • Goiter, Nodular

Interventions

  • Levothyroxin-NaDrug

    1 tablet 30 minutes before breakfast

  • Levothyroxine-Na + iodideDrug

    1 tablet 30 minutes before breakfast

  • IodideDrug

    1 tablet 30 minutes before breakfast

  • PlaceboDrug

    1 tablet 30 minutes before breakfast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary outcome measure is to compare the change in total volume of all nodules after 12 months Levothyroxin treatment to the change after 12 months of each of the reference treatments (one of the two active controls or placebo)Time frame: after 12 months of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sanofi-Aventis Administrative Office

    Frankfurt, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.